Anti-Therapeutic Action: dissociative effects

Ketamine induces multiple individually distinct whole-brain functional connectivity signatures

This study examined how ketamine, a promising depression treatment, affects different people’s brains in different ways. Rather than averaging brain scans across all participants, researchers looked at individual differences and found that each person showed unique patterns of brain activity changes. The research suggests that personalized approaches to ketamine treatment, based on individual brain responses, could help identify which patients would benefit most from the therapy.

Read More »

The Role of Psychedelics in the Treatment of Substance Use Disorders: An Overview of Systematic Reviews

This research review examines how psychedelic drugs like psilocybin and ketamine might help treat addiction. Studies show these substances could help people quit alcohol, drugs, and smoking by reducing cravings and promoting long-term abstinence. While results are promising, scientists caution that more rigorous research is needed before these treatments can be recommended for regular medical use, and they acknowledge real risks associated with these powerful drugs.

Read More »

Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation

Depression is a serious mental health condition affecting over 300 million people worldwide, with many patients not responding well to standard antidepressants. This review examines both traditional antidepressants like SSRIs and exciting new treatments including ketamine and psilocybin, as well as brain stimulation techniques. The key finding is that different treatments work through similar mechanisms—all ultimately enhancing brain cell connections and reducing inflammation—suggesting that combining different approaches might work better than single therapies.

Read More »

How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework

Psychedelic drugs like LSD and psilocybin show promise in treating depression with effects lasting months after single doses. However, scientists debate whether the hallucinations and mystical experiences these drugs produce are necessary for their healing effects. This review proposes a framework to test whether lower doses without hallucinations might still provide antidepressant benefits, similar to how anesthesia-administered ketamine works without the patient’s awareness.

Read More »
Scroll to Top